{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-014390","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.142258+00:00","generated_at":"2026-06-11T18:32:17.124859+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HOOKIPA Q2 net loss $18M; HB-200 Phase 2 shows 43% ORR in HPV16+ head and neck cancer","bullets":["Net loss $18.0M in Q2 2023 vs $16.4M in Q2 2022; revenue flat at $2.7M.","Cash $136.0M at June 30, 2023, up from $113.4M at Dec 31, 2022, after $50M June offering.","Phase 2 HB-200 + pembrolizumab: 43% ORR in CPI-naïve patients, double pembrolizumab alone; randomized trial planned H1 2024.","R&D expenses rose $3.6M to $19.7M on higher clinical costs for HB-200, HB-300, and partnered programs.","Exchange offer for 627,632 underwater options (exercise >$6.50) to eligible non-executive employees."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-014390","json":"https://secwatch.observer/filing/0001558370-23-014390.json","markdown":"https://secwatch.observer/filing/0001558370-23-014390.md","text":"https://secwatch.observer/filing/0001558370-23-014390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000155837023014390/0001558370-23-014390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000155837023014390/hook-20230810x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:32:17.124859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d4da692c8e785e9923a4b858a2f78ce325b3375","claim":"HOOKIPA Pharma Inc. reported second quarter of 2023 results: revenue $2.7 million.","evidence_excerpt":"The increase was primarily attributable to funds resulting from the follow-on financing in June 2023, partly offset by cash used in operating activities. ​ Revenue: Revenue was $2.7 million for the three months ended June 30, 2023 and for the three months ended June 30, 2022. A decrease of cost reimbursements received under the Restated Gilead Collaboration","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000155837023014390/0001558370-23-014390-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of 2023"},{"label":"Revenue","value":"$2.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}